Paul Hastings Advising Aardvark Therapeutics on Its IPO

Paul Hastings LLP is advising Aardvark Therapeutics, Inc. on its approximately $94.2 million IPO on the Nasdaq Global Select Market. The offering comprises 5,888,000 shares of common stock at a public offering price of $16.00 and is expected to close on February 14, subject to customary closing conditions. In addition, Aardvark has granted the underwriters a 30-day option to purchase up to an additional 883,200 shares of common stock at the public offering price, less underwriting discounts and commissions.

Aardvark is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

The Paul Hastings team is led by chair of the Corporate practice in Palo Alto Jeff Hartlin, partners Samantha Eldredge and Elizabeth Razzano, and associates Nina John, Shawn Kim and Elizabeth Fleming.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.